Страна: Новая Зеландия
Язык: английский
Источник: Medsafe (Medicines Safety Authority)
Metoprolol tartrate 1 mg/mL;
AstraZeneca Limited
Metoprolol tartrate 1 mg/mL
1 mg/mL
Solution for injection
Active: Metoprolol tartrate 1 mg/mL Excipient: Sodium chloride Water for injection
Ampoule, glass, 5 mL, 5 dose units
Prescription
Prescription
Ipca Laboratories Limited
Betaloc IV is indicated for the following indications: · Cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · Suspected or definite myocardial infarction.
Package - Contents - Shelf Life: Ampoule, glass, 5 mL - 5 dose units - 60 months from date of manufacture stored at or below 25°C protect from light
1981-08-28
Betaloc IV Data Sheet 050411 Copyright 1 NEW ZEALAND DATA SHEET NAME OF MEDICINE B ETALOC IV metoprolol tartrate 1 mg/mL injection PRESENTATION Ampoule – a clear, colourless liquid free from foreign particles containing 5 mL of 1 mg/mL metoprolol tartrate. USES ACTIONS Metoprolol is a beta 1 -selective beta-blocker, ie. it blocks beta 1 –receptors at doses much lower than those needed to block beta 2 -receptors. Metoprolol has an insignificant membrane-stabilising effect and does not display partial agonist activity. Metoprolol reduces or inhibits the agonistic effect on the heart of catecholamines (which are released during physical and mental stress). This means that the usual increase in heart rate, cardiac output, cardiac contractility and blood pressure, produced by the acute increase in catecholamines, is reduced by metoprolol. During high endogenous adrenaline levels metoprolol interferes much less with blood pressure control than non-selective beta-blockers. When mandatory, metoprolol , in combination with a beta 2 -agonist, may be given to patients with symptoms of obstructive pulmonary disease. When given together with a beta 2 -agonist, metoprolol in therapeutic doses interferes less than non-selective beta-blockers with the beta 2 -mediated bronchodilation caused by the beta 2 -agonist. Metoprolol interferes less with insulin release and carbohydrate metabolism than do non- selective beta-blockers. Metoprolol interferes much less with the cardiovascular response to hypoglycaemia than do non-selective beta-blockers. Short term studies have shown that metoprolol may cause a slight increase in triglycerides and a decrease in free fatty acids in the blood. In some cases, a small decrease in the high density lipoproteins (HDL) fraction has been observed, although to a lesser extent than that following non-selective beta-blockers. Howe Прочитать полный документ